Understanding how a specific cell death pathway affects inflammation and immunity
Transcriptional Outputs of the Necroptotic Pathway
['FUNDING_OTHER'] · UNIVERSITY OF WASHINGTON · NIH-11125032
This study is looking at a special kind of cell death called necroptosis to see how it affects the immune system and inflammation, which could help us understand diseases like cancer and autoimmune disorders better.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF WASHINGTON (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-11125032 on ClinicalTrials.gov |
What this research studies
This research investigates necroptosis, a type of cell death that plays a role in immune responses and diseases like cancer and autoimmunity. The study aims to uncover how the necroptotic pathway influences immune signaling and inflammation, focusing on specific proteins involved in this process. Researchers will conduct experiments in cultured cells and in live mice to observe the effects of necroptosis on immune responses and cytokine production. By understanding these mechanisms, the research hopes to clarify the relationship between cell death and inflammation.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with autoimmune diseases or cancers where necroptosis may play a significant role.
Not a fit: Patients with conditions unrelated to necroptosis or those not experiencing inflammation or immune dysregulation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for managing autoimmune diseases and cancer by targeting the necroptotic pathway.
How similar studies have performed: Previous research has shown promising results in understanding necroptosis and its implications in inflammation, suggesting that this approach could yield valuable insights.
Where this research is happening
SEATTLE, UNITED STATES
- UNIVERSITY OF WASHINGTON — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: OBERST, ANDREW ATWELL — UNIVERSITY OF WASHINGTON
- Study coordinator: OBERST, ANDREW ATWELL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Model, CancerModel